Journal of Medicinal Chemistry · 2008 · 58 citations · 51 references
Life SciencesMedicinal ChemistryMolecular BiologyDrug DesignDrug DiscoveryEnzymologyActive Site ArchitectureEnzyme Active SitesEnzyme InhibitionLigand BindingActive Site InteractionsActive Site MechanismsActive Site ResiduesEnzyme-inhibitor BindingEnzyme-substrate InteractionsHistone Deacetylase TargetsHistone DeacetylasesSubstrate Binding Sites
Histone deacetylase 1 (HDAC1) has been linked to cell growth and cell cycle regulation, which makes it a widely recognized target for anticancer drugs. Whereas variations of the metal-binding and capping groups of HDAC inhibitors have been studied extensively, the role of the linker region is less well known, despite the potency of inhibitors with diverse linkers, such as MS-275. To facilitate a drug design that targets HDAC1, we assessed the influence of residues in the 11 A channel of the HDAC1 active site on activity by using an alanine scan. The mutation of eight channel residues to alanine resulted in a substantial reduction in deacetylase activity. Molecular dynamics simulations indicated that alanine mutation results in significant movement of the active-site channel, which suggests that channel residues promote HDAC1 activity by influencing substrate interactions. With little characterization of HDAC1 available, the combined experimental and computational results define the active-site residues of HDAC1 that are critical for substrate/inhibitor binding and provide important insight into drug design.
51
Multiple sequence alignment with the Clustal series of programs
Nucleic Acids Research · 2003 · 4.9K citations · Full text
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Michael S. Finnin, Jill R. Donigian, Alona Cohen et al. · Nature · 1999 · 1.7K citations